Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARVN NYSE:IKT NASDAQ:PGEN NASDAQ:TBPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARVNArvinas$7.76+2.2%$7.29$5.90▼$31.28$554.01M2.171.50 million shs2.59 million shsIKTInhibikase Therapeutics$1.90+2.2%$1.90$1.12▼$4.20$141.25M0.92280,054 shs232,497 shsPGENPrecigen$1.82-1.1%$1.50$0.65▼$2.17$543.13M1.781.47 million shs1.66 million shsTBPHTheravance Biopharma$11.62-0.3%$10.42$7.44▼$11.88$582.52M-0.02258,065 shs187,306 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARVNArvinas+2.24%-1.65%+3.74%-9.77%-75.12%IKTInhibikase Therapeutics+2.15%-5.00%+9.20%+0.26%+27.52%PGENPrecigen-1.09%-4.71%+28.17%+30.94%+5.20%TBPHTheravance Biopharma-0.26%+1.40%+9.62%+34.80%+17.49%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARVNArvinas3.9376 of 5 stars4.34.00.00.02.12.51.3IKTInhibikase Therapeutics1.2352 of 5 stars3.31.00.00.00.00.00.6PGENPrecigen4.0772 of 5 stars3.50.00.04.73.91.70.6TBPHTheravance Biopharma1.7321 of 5 stars3.30.00.00.01.82.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARVNArvinas 2.55Moderate Buy$20.29161.46% UpsideIKTInhibikase Therapeutics 2.50Moderate Buy$6.50242.11% UpsidePGENPrecigen 3.00Buy$6.00229.67% UpsideTBPHTheravance Biopharma 2.67Moderate Buy$16.6042.86% UpsideCurrent Analyst Ratings BreakdownLatest IKT, PGEN, ARVN, and TBPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/27/2025TBPHTheravance BiopharmaBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$24.00 ➝ $25.006/17/2025TBPHTheravance BiopharmaJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$24.006/12/2025PGENPrecigenJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$6.006/2/2025ARVNArvinasHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$24.006/2/2025ARVNArvinasLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$10.00 ➝ $9.006/1/2025ARVNArvinasLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/15/2025ARVNArvinasUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$74.00 ➝ $21.005/15/2025PGENPrecigenCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight5/9/2025ARVNArvinasMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$12.00 ➝ $11.005/5/2025ARVNArvinasCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$10.00 ➝ $9.505/5/2025ARVNArvinasBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$20.00 ➝ $10.00(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARVNArvinas$263.40M2.15N/AN/A$8.17 per share0.95IKTInhibikase TherapeuticsN/AN/AN/AN/A$1.78 per shareN/APGENPrecigen$3.92M137.05N/AN/A$0.13 per share14.00TBPHTheravance Biopharma$64.38M9.02N/AN/A$3.57 per share3.25Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARVNArvinas-$198.90M-$0.66N/AN/AN/A-10.92%-7.74%-4.11%7/29/2025 (Estimated)IKTInhibikase Therapeutics-$19.03M-$2.67N/AN/AN/AN/A-350.63%-201.82%N/APGENPrecigen-$126.24M-$0.56N/AN/AN/A-3,728.87%-279.20%-79.74%8/13/2025 (Estimated)TBPHTheravance Biopharma-$56.42M-$1.18N/A33.20N/A-89.38%-32.37%-16.48%8/4/2025 (Estimated)Latest IKT, PGEN, ARVN, and TBPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025PGENPrecigen-$0.14N/AN/AN/A$0.67 millionN/A8/4/2025Q2 2025TBPHTheravance Biopharma-$0.12N/AN/AN/A$16.04 millionN/A7/29/2025Q2 2025ARVNArvinas-$0.87N/AN/AN/A$34.42 millionN/A5/14/2025Q1 2025PGENPrecigen-$0.08-$0.07+$0.01-$0.18$0.50 million$1.34 million5/8/2025Q1 2025TBPHTheravance Biopharma-$0.11-$0.27-$0.16-$0.27$28.08 million$15.39 million5/1/2025Q1 2025ARVNArvinas-$0.93$1.14+$2.07$1.14$41.87 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARVNArvinasN/AN/AN/AN/AN/AIKTInhibikase TherapeuticsN/AN/AN/AN/AN/APGENPrecigenN/AN/AN/AN/AN/ATBPHTheravance BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARVNArvinasN/A4.584.58IKTInhibikase TherapeuticsN/A0.850.85PGENPrecigenN/A3.533.53TBPHTheravance BiopharmaN/A4.774.77Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARVNArvinas95.19%IKTInhibikase Therapeutics3.81%PGENPrecigen33.51%TBPHTheravance Biopharma99.10%Insider OwnershipCompanyInsider OwnershipARVNArvinas4.73%IKTInhibikase Therapeutics7.30%PGENPrecigen47.10%TBPHTheravance Biopharma6.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARVNArvinas42072.99 million69.54 millionOptionableIKTInhibikase Therapeutics674.34 million66.18 millionNot OptionablePGENPrecigen190295.18 million156.15 millionOptionableTBPHTheravance Biopharma11050.00 million46.55 millionOptionableIKT, PGEN, ARVN, and TBPH HeadlinesRecent News About These CompaniesBrokerages Set Theravance Biopharma, Inc. (NASDAQ:TBPH) Target Price at $16.60July 17 at 3:41 AM | americanbankingnews.comInsider Selling: Theravance Biopharma, Inc. (NASDAQ:TBPH) SVP Sells 10,000 Shares of StockJuly 16 at 7:18 PM | marketbeat.com5 Small Drug Stocks to Buy Amid Trump's New Tariff ThreatsJuly 16 at 10:05 AM | zacks.comTheravance Biopharma (NASDAQ:TBPH) Stock Rating Lowered by Wall Street ZenJuly 14, 2025 | americanbankingnews.comTheravance Biopharma, Inc. (NASDAQ:TBPH) Given Consensus Recommendation of "Moderate Buy" by AnalystsJuly 12, 2025 | marketbeat.comTheravance Biopharma (NASDAQ:TBPH) Downgraded to "Hold" Rating by Wall Street ZenJuly 12, 2025 | marketbeat.comTheravance Biopharma (NASDAQ:TBPH) Trading Up 5.7% on Analyst UpgradeJune 27, 2025 | marketbeat.comTheravance Biopharma (NASDAQ:TBPH) Price Target Raised to $25.00 at BTIG ResearchJune 27, 2025 | marketbeat.comTBPH Theravance Biopharma, Inc. - Seeking AlphaJune 26, 2025 | seekingalpha.comTheravance Biopharma Announces Approval of YUPELRI® (revefenacin) by China's NMPAJune 26, 2025 | prnewswire.comTheravance Biopharma (NASDAQ:TBPH) Upgraded by Wall Street Zen to "Buy" RatingJune 21, 2025 | marketbeat.comInsider Selling: Theravance Biopharma, Inc. (NASDAQ:TBPH) SVP Sells 24,000 Shares of StockJune 5, 2025 | insidertrades.comTBPH to Sell Remaining Trelegy Royalty Interest to GSK, Stock RisesJune 3, 2025 | zacks.comTheravance Shares Rise Premarket on Sale of Trelegy RoyaltiesJune 2, 2025 | marketwatch.comTheravance hands off the last of its Trelegy royalties to GSK for $225MJune 2, 2025 | fiercepharma.comFTheravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 ...June 2, 2025 | gurufocus.comTheravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 ...June 2, 2025 | gurufocus.comTheravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 MillionJune 2, 2025 | prnewswire.comTheravance Biopharma at H.C. Wainwright: Strategic Focus on YUPELRI and AmpreloxetineMay 21, 2025 | investing.comTheravance Biopharma to Participate in an Upcoming Investor ConferenceMay 13, 2025 | prnewswire.comAnalysts Offer Insights on Healthcare Companies: ALX Oncology Holdings (ALXO), Collegium Pharmaceutical (COLL) and Theravance Biopharma (TBPH)May 11, 2025 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIKT, PGEN, ARVN, and TBPH Company DescriptionsArvinas NASDAQ:ARVN$7.76 +0.17 (+2.24%) Closing price 07/17/2025 04:00 PM EasternExtended Trading$7.82 +0.06 (+0.77%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.Inhibikase Therapeutics NYSE:IKT$1.90 +0.04 (+2.15%) Closing price 07/17/2025 04:00 PM EasternExtended Trading$1.90 0.00 (-0.26%) As of 07/17/2025 05:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.Precigen NASDAQ:PGEN$1.82 -0.02 (-1.09%) Closing price 07/17/2025 04:00 PM EasternExtended Trading$1.88 +0.06 (+3.52%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.Theravance Biopharma NASDAQ:TBPH$11.62 -0.03 (-0.26%) Closing price 07/17/2025 04:00 PM EasternExtended Trading$11.62 0.00 (0.00%) As of 07/17/2025 04:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Is Amazon Really the Best Forever Stock for Your Portfolio? Qualcomm: Undervalued Chip Stock in Breakout Uptrend Broadcom’s Takes on NVIDIA: Why Tomahawk Ultra Could Boost Shares CrowdStrike Bulls Beware: This Trade May Be Getting Crowded AMD Just Triggered a Signal Traders Can’t Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
